435 related articles for article (PubMed ID: 17107884)
21. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions.
Zhang Q; Kelly JW
Biochemistry; 2003 Jul; 42(29):8756-61. PubMed ID: 12873136
[TBL] [Abstract][Full Text] [Related]
22. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition.
Julius RL; Hawthorne MF
Drug News Perspect; 2008 Jun; 21(5):258-66. PubMed ID: 18596990
[TBL] [Abstract][Full Text] [Related]
23. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
24. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation.
Johnson SM; Petrassi HM; Palaninathan SK; Mohamedmohaideen NN; Purkey HE; Nichols C; Chiang KP; Walkup T; Sacchettini JC; Sharpless KB; Kelly JW
J Med Chem; 2005 Mar; 48(5):1576-87. PubMed ID: 15743199
[TBL] [Abstract][Full Text] [Related]
25. Trans-suppression of misfolding in an amyloid disease.
Hammarström P; Schneider F; Kelly JW
Science; 2001 Sep; 293(5539):2459-62. PubMed ID: 11577236
[TBL] [Abstract][Full Text] [Related]
26. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.
Sebastião MP; Lamzin V; Saraiva MJ; Damas AM
J Mol Biol; 2001 Mar; 306(4):733-44. PubMed ID: 11243784
[TBL] [Abstract][Full Text] [Related]
27. CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.
Qiang L; Guan Y; Li X; Liu L; Mu Y; Sugano A; Takaoka Y; Sakaeda T; Imbimbo BP; Yamamura KI; Jin S; Li Z
Amyloid; 2017 Mar; 24(1):42-51. PubMed ID: 28393633
[TBL] [Abstract][Full Text] [Related]
28. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization.
Hurshman AR; White JT; Powers ET; Kelly JW
Biochemistry; 2004 Jun; 43(23):7365-81. PubMed ID: 15182180
[TBL] [Abstract][Full Text] [Related]
29. Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis.
Sörgjerd K; Ghafouri B; Jonsson BH; Kelly JW; Blond SY; Hammarström P
J Mol Biol; 2006 Feb; 356(2):469-82. PubMed ID: 16376939
[TBL] [Abstract][Full Text] [Related]
30. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
[TBL] [Abstract][Full Text] [Related]
31. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
Miller SR; Sekijima Y; Kelly JW
Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
[TBL] [Abstract][Full Text] [Related]
32. Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding.
Miyata M; Sato T; Mizuguchi M; Nakamura T; Ikemizu S; Nabeshima Y; Susuki S; Suwa Y; Morioka H; Ando Y; Suico MA; Shuto T; Koga T; Yamagata Y; Kai H
Biochemistry; 2010 Jan; 49(1):114-23. PubMed ID: 19950966
[TBL] [Abstract][Full Text] [Related]
33. Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers.
Lai Z; McCulloch J; Lashuel HA; Kelly JW
Biochemistry; 1997 Aug; 36(33):10230-9. PubMed ID: 9254621
[TBL] [Abstract][Full Text] [Related]
34. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
35. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
36. Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange.
Tsai FJ; Nelson LT; Kline GM; Jäger M; Berk JL; Sekijima Y; Powers ET; Kelly JW
Amyloid; 2023 Jun; 30(2):220-224. PubMed ID: 36444793
[TBL] [Abstract][Full Text] [Related]
37. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.
Yokoyama T; Mizuguchi M
Biol Pharm Bull; 2018; 41(7):979-984. PubMed ID: 29962408
[TBL] [Abstract][Full Text] [Related]
39. Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors.
Dolado I; Nieto J; Saraiva MJ; Arsequell G; Valencia G; Planas A
J Comb Chem; 2005; 7(2):246-52. PubMed ID: 15762752
[TBL] [Abstract][Full Text] [Related]
40. Prevention of transthyretin amyloid disease by changing protein misfolding energetics.
Hammarström P; Wiseman RL; Powers ET; Kelly JW
Science; 2003 Jan; 299(5607):713-6. PubMed ID: 12560553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
